Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > Yup stickyscamo moving up after hours
View:
Post by Dibah420 on May 28, 2021 6:17pm

Yup stickyscamo moving up after hours

Liminal BioSciences Inc. Common Shares (LMNL)

$4.42
+0.19 (+4.49%)
CLOSED AT 4:00 PM ET ON MAY 28, 2021
$4.21
-0.21 (-4.75%)
Comment by realstocky on May 28, 2021 6:20pm
This post has been removed in accordance with Community Policy
Comment by Transit77 on May 28, 2021 6:28pm
Wow nothing left in the pipe line my friend. It's all over as predicted Fezapregas is no longer viable. What now Realcamo???? What now the company is officially done. Great news and good end to these thieves. I'm very happy it's over and no one has to suffer any further.  
Comment by stockman6767 on May 28, 2021 6:54pm
Yup, if we are lucky, maybe Mad Cow Disease will have a revival.  But I think we sold off that purifiacation technology too.
Comment by Dibah420 on May 29, 2021 12:28pm
************************************************************************************************************** Your sarcasm is apropos. Mad Cow project was based on an earlier cognate of PBI 4050. I believe it was PBI 1402.  Our friend sah1 spent eons reporting on minutes of parliamentary committees but it came to naught.  UK govt couldn't justify the cost...or it was too cheap and ...more  
Comment by stockbuphoon on May 28, 2021 7:11pm
Newcamo, you sound ridiculous - normal course of business releasing bad news on Friday 2 weeks after saying small molecule is their only focus! Tomfvck is either shutting doors and selling 4050 privately or the entire thing was a total scam. if they got a voucher, they have to wait a long time to sell it and they have put Phase 1 MAD trial on hold. Why would they not finish trial as it's ...more  
Comment by Transit77 on May 28, 2021 7:17pm
Loved this post. Well said it's over ain't going to be no review voucher. Nothing but  $0000000000000000000000's : ) They are done. 
Comment by realstocky on May 28, 2021 7:22pm
This post has been removed in accordance with Community Policy
Comment by stockbuphoon on May 28, 2021 9:49pm
Wait and see, Newcamo/Realstocky (same guy). They have nothing remotely close to phase 1 trials after they ditch Fez/4050. It will take years. They have no money spending $18M a quarter AFTER selling plasma. See slide 5 of Q1 presentation. They are dead on arrival on June 4th. Pritchard and Sartore should be fired immediately - well, 10 years ago - what have they accomplished? Look at the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities